Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Maintenance After CCRT in Locally Advanced Cervical Cancer
NCT06251388Phase 2Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by West China Second University Hospital. Primary endpoint: Progression-free survival at 24 months. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06251388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251388.